E Fund Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $301K | Buy |
33,592
+9,918
| +42% | +$88.9K | 0.01% | 302 |
|
|
2025
Q1 | $178K | Buy |
23,674
+7,062
| +43% | +$53K | 0.01% | 370 |
|
|
2024
Q4 | $125K | Sell |
16,612
-7,226
| -30% | -$54.3K | 0.01% | 376 |
|
|
2024
Q3 | $181K | Sell |
23,838
-4,447
| -16% | -$33.8K | 0.01% | 336 |
|
|
2024
Q2 | $175K | Sell |
28,285
-45,895
| -62% | -$284K | 0.01% | 298 |
|
|
2024
Q1 | $377K | Buy |
74,180
+22,863
| +45% | +$116K | 0.02% | 236 |
|
|
2023
Q4 | $307K | Buy |
51,317
+9,820
| +24% | +$58.8K | 0.02% | 228 |
|
|
2023
Q3 | $294K | Sell |
41,497
-10,926
| -21% | -$77.4K | 0.02% | 213 |
|
|
2023
Q2 | $369K | Buy |
52,423
+5,838
| +13% | +$41.1K | 0.03% | 190 |
|
|
2023
Q1 | $389K | Buy |
46,585
+6,330
| +16% | +$52.9K | 0.03% | 175 |
|
|
2022
Q4 | $462K | Buy |
40,255
+4,838
| +14% | +$55.5K | 0.04% | 145 |
|
|
2022
Q3 | $446K | Sell |
35,417
-8,991
| -20% | -$113K | 0.04% | 146 |
|
|
2022
Q2 | $470K | Buy |
44,408
+27,767
| +167% | +$294K | 0.04% | 154 |
|
|
2022
Q1 | $271K | Buy |
16,641
+1,756
| +12% | +$28.6K | 0.01% | 233 |
|
|
2021
Q4 | $206K | Buy |
14,885
+3,536
| +31% | +$48.9K | 0.01% | 256 |
|
|
2021
Q3 | $163K | Buy |
+11,349
| New | +$163K | 0.01% | 242 |
|
|
2021
Q1 | $112K | Buy |
+10,970
| New | +$112K | 0.01% | 236 |
|